肺癌与胃肠道癌症中风险导向的门诊血栓预防:TARGET-TP随机临床试验
TARGET-TP是一项开放标签3期随机临床试验,2018年6月至2021年7月在澳大利亚5家医院纳入328例接受系统抗癌治疗的肺癌或胃肠道癌症成人。基于纤维蛋白原和D-二聚体的风险分层将患者分为低风险(观察)和高风险(随机)队列,高风险患者1:1随机接受依诺肝素40 mg皮下每日一次90天(按持续风险延长至180天)或无血栓预防。结果显示风险导向血栓预防减少血栓栓塞且不增加安全顾虑,并降低死亡率。
要点
- 高风险队列中依诺肝素组血栓栓塞8% vs 对照组23%(HR 0.31,95%CI 0.15-0.70,P=.005),需治疗人数6.7。
- 低风险组血栓栓塞8%,高风险对照组较低风险组HR 3.33(95%CI 1.58-6.99,P=.002)。
- 大出血发生率低,依诺肝素组1%、高风险对照组2%、低风险组2%(P=.88)。
核心结论
- 在按血栓风险评分分层的肺癌和胃肠道癌症患者中,风险导向血栓预防减少血栓栓塞,需治疗人数理想,无安全顾虑,并降低死亡率。
- 低风险个体避免了不必要的干预。
- 研究结果提示,生物标志物驱动的风险导向一级血栓预防是该人群的适当方法。
研究设计与样本
- 开放标签3期随机临床试验(TARGET-TP),2018年6月至2021年7月(主要随访6个月),在澳大利亚1家城市和4家区域医院进行。
- 纳入18岁及以上、因肺癌或胃肠道癌症开始系统抗癌治疗的成人;基于纤维蛋白原和D-二聚体水平的血栓栓塞风险评估将个体分为低风险(观察)和高风险(随机)队列。
- 782例合格成人中328例(42%)入组;中位年龄65岁(范围30-88岁),男性176例(54%)。
- 201例(61%)为胃肠道癌症,127例(39%)为肺癌,132例(40%)有转移性疾病;200例(61%)为高风险(每组100例),128例(39%)为低风险。
- 高风险患者1:1随机接受依诺肝素40 mg皮下每日一次90天(按持续风险延长至180天)或无血栓预防(对照)。
主要发现
- 高风险队列中,依诺肝素组8例(8%)发生血栓栓塞,对照组23例(23%)(HR 0.31;95%CI 0.15-0.70;P=.005;需治疗人数6.7)。
- 低风险组10例(8%)发生血栓栓塞(高风险对照组 vs 低风险组:HR 3.33;95%CI 1.58-6.99;P=.002)。
- 风险模型敏感性70%,特异性61%。
- 大出血发生率低:依诺肝素组1例(1%),高风险对照组2例(2%),低风险组3例(2%)(P=.88)。
- 6个月死亡率:依诺肝素组13% vs 高风险对照组26%(HR 0.48;95%CI 0.24-0.93;P=.03);低风险组7%(vs 高风险对照组:HR 4.71;95%CI 2.13-10.42;P<.001)。
关键数值与推荐
- 高风险队列:依诺肝素组血栓栓塞8% vs 对照组23%(HR 0.31;95%CI 0.15-0.70;P=.005;需治疗人数6.7)。
- 高风险对照组 vs 低风险组血栓栓塞:HR 3.33(95%CI 1.58-6.99;P=.002)。
- 风险模型敏感性70%,特异性61%。
- 大出血:依诺肝素组1% vs 高风险对照组2% vs 低风险组2%(P=.88)。
- 6个月死亡率:依诺肝素组13% vs 高风险对照组26%(HR 0.48;95%CI 0.24-0.93;P=.03);低风险组7%(vs 高风险对照组:HR 4.71;95%CI 2.13-10.42;P<.001)。
临床怎么用
- 作者认为,生物标志物驱动的风险导向一级血栓预防是该人群的适当方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Thromboprophylaxis for individuals receiving systemic anticancer therapies has proven to be effective. Potential to maximize benefits relies on improved risk-directed strategies, but existing risk models underperform in cohorts with lung and gastrointestinal cancers. OBJECTIVE: To assess clinical benefits and safety of biomarker-driven thromboprophylaxis and to externally validate a biomarker thrombosis risk assessment model for individuals with lung and gastrointestinal cancers. DESIGN, SETTING, AND PARTICIPANTS: This open-label, phase 3 randomized clinical trial (Targeted Thromboprophylaxis in Ambulatory Patients Receiving Anticancer Therapies [TARGET-TP]) conducted from June 2018 to July 2021 (with 6-month primary follow-up) included adults aged 18 years or older commencing systemic anticancer therapies for lung or gastrointestinal cancers at 1 metropolitan and 4 regional hospitals in Australia. Thromboembolism risk assessment based on fibrinogen and d-dimer levels stratified individuals into low-risk (observation) and high-risk (randomized) cohorts. INTERVENTIONS: High-risk patients were randomized 1:1 to receive enoxaparin, 40 mg, subcutaneously daily for 90 days (extending up to 180 days according to ongoing risk) or no thromboprophylaxis (control). MAIN OUTCOMES AND MEASURES: The primary outcome was objectively confirmed thromboembolism at 180 days. Key secondary outcomes included bleeding, survival, and risk model validation. RESULTS: Of 782 eligible adults, 328 (42%) were enrolled in the trial (median age, 65 years [range, 30-88 years]; 176 male [54%]). Of these participants, 201 (61%) had gastrointestinal cancer, 127 (39%) had lung cancer, and 132 (40%) had metastatic disease; 200 (61%) were high risk (100 in each group), and 128 (39%) were low risk. In the high-risk cohort, thromboembolism occurred in 8 individuals randomized to enoxaparin (8%) and 23 control individuals (23%) (hazard ratio [HR], 0.31; 95% CI, 0.15-0.70; P = .005; number needed to treat, 6.7). Thromboembolism occurred in 10 low-risk individuals (8%) (high-risk control vs low risk: HR, 3.33; 95% CI, 1.58-6.99; P = .002). Risk model sensitivity was 70%, and specificity was 61%. The rate of major bleeding was low, occurring in 1 participant randomized to enoxaparin (1%), 2 in the high-risk control group (2%), and 3 in the low-risk group (2%) (P = .88). Six-month mortality was 13% in the enoxaparin group vs 26% in the high-risk control group (HR, 0.48; 95% CI, 0.24-0.93; P = .03) and 7% in the low-risk group (vs high-risk control: HR, 4.71; 95% CI, 2.13-10.42; P < .001). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of individuals with lung and gastrointestinal cancers who were stratified by risk score according to thrombosis risk, risk-directed thromboprophylaxis reduced thromboembolism with a desirable number needed to treat, without safety concerns, and with reduced mortality. Individuals at low risk avoided unnecessary intervention. The findings suggest that biomarker-driven, risk-directed primary thromboprophylaxis is an appropriate approach in this population. TRIAL REGISTRATION: ANZCTR Identifier: ACTRN12618000811202.
引用
- Alexander M, Harris S, Underhill C, et al. Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 37733336. doi:10.1001/jamaoncol.2023.3634
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。